A bispecific CD30xCD16 engager was able to direct PB-NK and CB-NK cells to increase cytotoxicity against CD30+ lymphomas in a pre-clinical study both in vitro and in vivo (148). The gene discussed is TNFRSF8; the disease is lymphoma.